Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418234 | 0.85 | NUDT1 (0.49) | ROCK2ROCK1NUDT1CASP1PIM1 | |
| SCHEMBL30843210 | 0.85 | NUDT1 (0.49) | ROCK2ROCK1NUDT1CASP1PIM1 | |
| SCHEMBL8707407 | 0.81 | ROCK2 (0.65) | ROCK2ROCK1CYP11B2TYK2JAK2 | |
| SCHEMBL8485471 | 0.81 | ROCK2 (0.59) | ROCK2ROCK1PIM1PIM2BAD | |
| SCHEMBL30107188 | 0.79 | SIRT3 (0.61) | ROCK2ROCK1NUDT1CASP1TYK2 | |
| SCHEMBL13162016 | 0.79 | SIRT3 (0.61) | ROCK2ROCK1NUDT1CASP1TYK2 | |
| SCHEMBL31678780 | 0.79 | KDM4C (0.58) | ROCK2ROCK1NUDT1CASP1PIM1 | |
| SCHEMBL16676647 | 0.79 | KDM4C (0.58) | ROCK2ROCK1NUDT1CASP1PIM1 | |
| SCHEMBL15140751 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1CYP11B2TYK2JAK2 | |
| SCHEMBL31750890 | 0.79 | ROCK2 (0.61) | ROCK2ROCK1CYP11B2TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005038043-A2 | METHODS OF DETECTING POLY (ADP-RIBOSE) POLYMERASE AND OTHER NAD+UTILIZING ENZYMES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| US-6800652-B2 | SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040097509-A1 | Diaryl compounds | PFIZER INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097509-A1 | Diaryl compounds | CCNL2, CCNI, CCNA1 | ROCK2 3015/4885ROCK1 1832/4885NUDT1 1263/4885 |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | CSF1R, CSF3R, FLT3 | ROCK2 2104/4885ROCK1 1227/4885NUDT1 2729/4885 |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | PARP1, PARP11, PARP3 | ROCK2 3981/4885ROCK1 3833/4885NUDT1 35/4885 |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | CSF1R, CSF3R, FLT3 | ROCK2 2104/4885ROCK1 1227/4885NUDT1 2729/4885 |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | SLC6A4, SLC6A2, SLC6A3 | ROCK2 1154/4885ROCK1 820/4885NUDT1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.